Компоненты микроокружения сарком мягких тканей. Часть 1

Саркомы мягких тканей (СМТ) – редкая гетерогенная группа злокачественных новообразований, характеризующаяся агрессивным течением и плохим ответом на лечение. Это обусловливает актуальность исследований, направленных на изучение патогенеза данной патологии. Опухолевое микроокружение состоит из стромальных и иммунных клеток, кровеносных и лимфатических сосудов, а также внеклеточного матрикса. К настоящему времени известно, что для СМТ характерны сложные взаимоотношения между опухолевыми клетками и компонентами микроокружения. Динамические взаимодействия между ними усиливают адаптацию к меняющимся условиям окружающей среды, что обеспечивает высокий агрессивный потенциал СМТ и устойчивость к противоопухолевой терапии. Фундаментальные исследования, направленные на изучение роли компонентов микроокружения в канцерогенезе СМТ, могут послужить ключом к открытию как новых биомаркеров – предикторов прогноза, так и мишеней для противоопухолевых препаратов. Данная статья посвящена роли компонентов микроокружения СМТ в канцерогенезе и их взаимодействию с клетками этой опухоли.

1. Blay J.Y. Evolution in soft tissue sarcoma. Future Oncol 2017;13(1s):1–2. DOI: 10.2217/fon-2016-0497

2. Almas T., Khan M.K., Murad M.F. et al. Clinical and pathological characteristics of soft tissue sarcomas: a retrospective study from a developing country. Cureus 2020;12(8):e9913. DOI: 10.7759/cureus.9913

3. Ramu E.M., Houdek M.T., Isaac C.E. et al. Management of soft-tissue sarcomas; treatment strategies, staging, and outcomes. SICOT J 2017;3:20. DOI: 10.1051/sicotj/2017010

4. Gerrand C.H., Bell R.S., Wunder J.S. et al. The influence of anatomic location on outcome in patients with soft tissue sarcoma of the extremity. Cancer 2003;97(2):485–92. DOI: 10.1002/cncr.11076

5. Chintamani. Soft tissue sarcomas-the pitfalls in diagnosis and management. Indian J Surg Oncol 2011;2(4):261–4. DOI: 10.1007/s13193-012-0141-7

6. Hatina J., Kripnerova M., Houfkova K. et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol 2019;1123:95–118. DOI: 10.1007/978-3-030-11096-3_7

7. Zeng D., Li M., Zhou R., Zhang J. et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res 2019;7(5):737–50. DOI: 10.1158/2326-6066.CIR-18-0436

8. Deng J., Zeng W., Kong W. et al. The study of sarcoma microenvironment heterogeneity associated with prognosis based on an immunogenomic landscape analysis. Front Bioeng Biotechnol 2020;8:1003. DOI: 10.3389/fbioe.2020.01003

9. Wang Q., Shao X., Zhang Y. et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 2023;12(10):11149–65. DOI: 10.1002/cam4.5698

10. Tessaro F.H., Ko E.Y., De Simone M. et al. Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumorexpressed MIF in shaping macrophage heterogeneity. Cell Rep 2022;39(12):110977. DOI: 10.1016/j.celrep.2022.110977

11. Petitprez F., de Reyniès A., Keung E.Z. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577(7791):556–60. DOI: 10.1038/s41586-019-1906-8

12. Stahl D., Gentles A.J., Thiele R. et al. Prognostic profiling of the immune cell microenvironment in Ewing’s Sarcoma Family of Tumors. Oncoimmunology 2019;8(12):e1674113. DOI: 10.1080/2162402X.2019.1674113

13. Hu C., Chen B., Huang Z. et al. Comprehensive profiling of immunerelated genes in soft tissue sarcoma patients. J Translat Med 2020;18:1–18. DOI: 10.1186/s12967-020-02512-8

14. Gu H.Y., Lin L.L., Zhang C. et al. The potential of five immune-related prognostic genes to predict survival and response to immune checkpoint inhibitors for soft tissue sarcomas based on multi-omic study. Front Oncol 2020;10:1317. DOI: 10.3389/fonc.2020.01317

15. Tsagozis P., Augsten M., Zhang Y. et al. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunol Immunother 2019;68(6):927–36. DOI: 10.1007/s00262-019-02322-y

16. Dufresne A., Lesluyes T., Ménétrier-Caux C. et al. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. Oncoimmunology 2020;9(1):1792036. DOI: 10.1080/2162402X.2020.1792036

17. Zhu N., Hou J. Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma. Cancer Cell Int 2020;20(1):1–11. DOI: 10.1186/s12935-020-01672-3

18. Zhou J., Tang Z., Gao S. et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol 2020;10:188. DOI: 10.3389/fonc.2020.00188

19. Mantovani A., Marchesi F., Malesci A. et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14(7):399–416. DOI: 10.1038/nrclinonc.2016.217

20. Najafi M., Hashemi Goradel N., Farhood B. et al. Macrophage polarity in cancer: a review. J Cell Biochem 2019;120(3):2756–65. DOI: 10.1002/jcb.27646

21. Nyström H., Jönsson M., Nilbert M. et al. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumorassociated macrophages and B-cells. Acta Oncol 2023;62(1):33–9. DOI: 10.1080/0284186X.2023.2172688

22. Seong G., D’Angelo S.P. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas. Front Oncol 2023;13:1150765. DOI: 10.3389/fonc.2023.1150765

23. Cheng S., Li Z., Gao R., Xing B. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 2021;184(3):792–809. DOI: 10.1016/j.cell.2021.01.010

24. El-Kenawi A., Dominguez-Viqueira W., Liu M. et al. Macrophagederived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res 2021;81(21):5477–90. DOI: 10.1158/0008-5472.CAN-20-4028

25. Cassetta L., Pollard J.W. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 2018;17(12):887–904. DOI: 10.1038/nrd.2018.169

26. Fujiwara T., Yakoub M.A., Chandler A. et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther 2021;20(8):1388–99. DOI: 10.1158/1535-7163.MCT-20-0591

27. Lee C.H., Espinosa I., Vrijaldenhoven S. et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008;14(5):1423–30. DOI: 10.1158/1078-0432.CCR-07-1712

28. Nabeshima A., Matsumoto Y., Fukushi J. et al.Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/ Akt pathways. B J Cancer 2015;112(3):547–55. DOI: 10.1038/bjc.2014.637

29. Oike N., Kawashima H., Ogose A. et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 2018;109(10):3043–54. DOI: 10.1111/cas.13769

30. Kather J.N., Hörner C., Weis C.A. et al. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep 2019;9(1):9211. DOI: 10.1038/s41598-019-45551-y

31. Minopoli M., Sarno S., Cannella L. et al. Crosstalk between macrophages and myxoid liposarcoma cells increases spreading and invasiveness of tumor cells. Cancers 2021;13(13):3298. DOI: 10.3390/cancers13133298

32. Qayoom H., Sofi S., Mir M.A. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. Immunol Res 2023;71(4):588–99. DOI: 10.1007/s12026-023-09376-2

33. Badalamenti G., Fanale D., Incorvaia L. et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol 2019;343:103753. DOI: 10.1016/j.cellimm.2018.01.013

34. Smolle M.A., Herbsthofer L., Granegger B. et al. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: A clinicopathological study. Br J Cancer 2021;25(5):717–24. DOI: 10.1038/s41416-021-01456-0

35. Hemminger J.A., Iwenofu O.H. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms. Mod Pathol 2013;26(9):1204–10. DOI: 10.1038/modpathol.2013.65

36. Sorbye S.W., Kilvaer T., Valkov A. et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011;6(1):e14611. DOI: 10.1371/journal.pone.0014611

37. Pollack S.M., He Q., Yearley J.H. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123(17):3291–304. DOI: 10.1002/cncr.30726

38. Nakajima K., Raz A. T-cell infiltration profile in musculoskeletal tumors. J Orthop Res 2021;39(3):536–42. DOI: 10.1002/jor.24890

39. Fujii H., Arakawa A., Utsumi D. et al. CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int Journal Cancer 2014;134(10):2393–402. DOI: 10.1002/ijc.28581

40. Van Erp A.E., Versleijen-Jonkers Y.M., Hillebrandt-Roeffen M.H. et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget 2017;8(41):71371. DOI: 10.18632/oncotarget.19071

41. Nowicki T.S., Akiyama R., Huang R.R. et al. Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res 2017;5(2):118–26. DOI: 10.1158/2326-6066.CIR-16-0148

42. Liu Y., Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med 2016;94(5):509–22. DOI: 10.1007/s00109-015-1376-x

43. D’Angelo S.P., Shoushtari A.N., Agaram N.P. et al. Prevalence of tumorinfiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathol 2015;46(3):357–65. DOI: 10.1016/j.humpath.2014.11.001

44. Li L.J., Shi Y.C., Luo M.X. et al. Effects of moxibustion on Treg cells in sarcoma microenvironment. Journal of Integrative Medicine 2021;19(3):251–7. DOI: 10.1016/j.joim.2021.02.001

45. Que Y., Xiao W., Guan Y.X. et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer 2017;8(11):2018. DOI: 10.7150/jca.18683

46. Keung E.Z., Burgess M., Salazar R. et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 2020;26(6):1258–66. DOI: 10.1158/1078-0432.CCR-19-1824

47. Judge S.J., Darrow M.A., Thorpe S.W. et al. Analysis of tumorinfiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. J Immunother Cancer 2020;8(2):e001355. DOI: 10.1136/jitc-2020-001355

48. Sharonov G.V., Serebrovskaya E.O., Yuzhakova D.V. et al. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nature Rev Immunol 2020;20(5):294–307. DOI: 10.1038/s41577-019-0257-x

49. Premkumar K., Shankar B.S. TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma. Cancer Immunol Immunother 2021;70(1):153–68. DOI: 10.1007/s00262-020-02666-w

50. Tseng W.W., Malu S., Zhang M. et al. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460. DOI: 10.1155/2015/547460

51. Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–11. DOI: 10.1371/journal.pone.0014611

52. Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–10. DOI: 10.1186/1472-6890-12-5

53. Lazar A.J., McLellan M.D., Bailey M.H. et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017;171(4):950–65. DOI: 10.1016/j.cell.2017.10.014

54. Sousa L.M., Almeida J.S., Fortes-Andrade T. et al. Tumor and peripheral immune status in soft tissue sarcoma: implications for immunotherapy. Cancers 2021;13(15):3885. DOI: 10.3390/cancers13153885

55. Ponzetta A., Carriero R., Carnevale S. et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell 2019;178(2):346–60. DOI: 10.1016/j.cell.2019.05.047

56. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16(9):582–98. DOI: 10.1038/nrc.2016.73

57. Joshi R.S., Kanugula S.S., Sudhir S. et al. The role of cancer-associated fibroblasts in tumor progression. Cancers 2021;13(6):1399. DOI: 10.3390/cancers13061399

58. LeBleu V.S., Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 2018;11(4):dmm029447. DOI: 10.1242/dmm.029447

59. Erdogan B., Webb D.J. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 2017;45(1):229–36. DOI: 10.1042/BST20160387

60. Kudo A., Yoshimoto S., Yoshida H. et al. Biological features of canine cancer-associated fibroblasts and their influence on cancer cell invasion. J Vet Med Sci 2022;84(6):784–91. DOI: 10.1292/jvms.22-0041

61. Feng C., Kou L., Yin P. et al. Excessive activation of IL­33/ST2 in cancer­associated fibroblasts promotes invasion and metastasis in ovarian cancer. Oncol Lett 2022;23(5):1–12. DOI: 10.3892/ol.2022.13278

62. Komohara Y., Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol 2017;241(3):313–5. DOI: 10.1002/path.4824

63. Harati K., Daigeler A., Hirsch T. et al. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med 2016;37(6):1535–41. DOI: 10.3892/ijmm.2016.2556

64. Wright K., Ly T., Kriet M. et al. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 2023;1(6):1899. DOI: 10.3390/cancers15061899

65. Huang H., Wang Z., Zhang Y. et al Mesothelial cell-derived antigenpresenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 2022;40(6):656–73. DOI: 10.1016/j.ccell.2022.04.011

66. Mao X., Xu J., Wang W., Liang C. et al. Crosstalk between cancerassociated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021;20(1):1–30. DOI: 10.1186/s12943-021-01428-1

67. Manzur M., Hamzah J., Ganss R. Modulation of the “blood-tumor” barrier improves immunotherapy. Cell Cycle 2008;7(16):2452–5. DOI: 10.4161/cc.7.16.6451

68. Lee C.T., Mace T., Repasky E.A. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 2010;26(3):232–46. DOI: 10.3109/02656731003601745

69. Nordsmark M., Alsner J., Keller J. et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84(8):1070–5. DOI: 10.1054/bjoc.2001.1728

70. Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441(7092): 437–43. DOI: 10.1038/nature04871

71. Aggerholm-Pedersen N., Sørensen B.S., Overgaard J. et al. A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. Br J Cancer 2016;115(9):1096–104. DOI: 10.1038/bjc.2016.310

72. Nyström H., Jönsson M., Werner-Hartman L. et al. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall. J Clin Pathol 2017;70(10):879–85. DOI: 10.1136/jclinpath-2016-204149

73. Pakos E.E., Goussia A.C., Tsekeris P.G. et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005;25(5):3591–6.

74. Yudoh K., Kanamori M., Ohmori K. et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84(12):1610–5. DOI: 10.1054/bjoc.2001.1837

75. Hayes A.J., Mostyn-Jones A., Koban M.U. et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91(2):242–7. DOI: 10.1002/bjs.4398

76. Tomlinson J., Barsky S.H., Nelson S. et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5(11):3516–22.

77. Tammela T., Zarkada G., Wallgard E. et al. VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454(7204):656–60. DOI: 10.1038/nature07083

78. Yoon S.S., Segal N.H., Park P.J. et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006;135(2):282–90. DOI: 10.1016/j.jss.2006.01.023

79. Kilvaer T.K., Valkov A., Sorbye S.W. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med 2011;9:104. DOI: 10.1186/1479-5876-9-104

80. Rocchi L., Caraffi S., Perris R. et al. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep 2014;34(6):e00147. DOI: 10.1042/BSR20140075